GB201223244D0 - Micrornas as therapeutics and biomarkers for epilepsy - Google Patents

Micrornas as therapeutics and biomarkers for epilepsy

Info

Publication number
GB201223244D0
GB201223244D0 GBGB1223244.3A GB201223244A GB201223244D0 GB 201223244 D0 GB201223244 D0 GB 201223244D0 GB 201223244 A GB201223244 A GB 201223244A GB 201223244 D0 GB201223244 D0 GB 201223244D0
Authority
GB
United Kingdom
Prior art keywords
micrornas
biomarkers
epilepsy
therapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1223244.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
UCB Pharma GmbH
Rheinische Friedrich Wilhelms Universitaet Bonn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Pharma GmbH, Rheinische Friedrich Wilhelms Universitaet Bonn filed Critical UCB Pharma GmbH
Priority to GBGB1223244.3A priority Critical patent/GB201223244D0/en
Publication of GB201223244D0 publication Critical patent/GB201223244D0/en
Priority to PCT/EP2013/077836 priority patent/WO2014096418A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1223244.3A 2012-12-21 2012-12-21 Micrornas as therapeutics and biomarkers for epilepsy Ceased GB201223244D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1223244.3A GB201223244D0 (en) 2012-12-21 2012-12-21 Micrornas as therapeutics and biomarkers for epilepsy
PCT/EP2013/077836 WO2014096418A2 (en) 2012-12-21 2013-12-20 Micrornas as therapeutics and biomarkers for epilepsy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1223244.3A GB201223244D0 (en) 2012-12-21 2012-12-21 Micrornas as therapeutics and biomarkers for epilepsy

Publications (1)

Publication Number Publication Date
GB201223244D0 true GB201223244D0 (en) 2013-02-06

Family

ID=47682463

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1223244.3A Ceased GB201223244D0 (en) 2012-12-21 2012-12-21 Micrornas as therapeutics and biomarkers for epilepsy

Country Status (2)

Country Link
GB (1) GB201223244D0 (en)
WO (1) WO2014096418A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114410765A (en) * 2022-01-17 2022-04-29 上海大学 Application of miRNA molecular marker in schizophrenia detection
RU2815113C1 (en) * 2023-12-19 2024-03-11 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого" Министерства Здравоохранения Российской Федерации Oligonucleotides for diagnosing epilepsy by quantitative pcr

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066034A1 (en) 2013-10-28 2015-05-07 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating neuronal excitability and motor behavior
US20180327845A1 (en) * 2015-11-18 2018-11-15 Dignity Health Methods of diagnosing epilepsy
US10982214B2 (en) * 2016-07-20 2021-04-20 Thomas Jefferson University Inhibiting microRNA to prevent development of essential hypertension
CN108403711B (en) * 2017-02-10 2020-07-31 中国科学院上海营养与健康研究所 MicroRNA for detecting and treating inflammatory bowel disease
CN111263811A (en) * 2017-08-25 2020-06-09 多伦多大学理事会 Compositions and methods for detecting and treating insulin resistance
CA3079524A1 (en) * 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
KR20200119782A (en) 2017-12-06 2020-10-20 오비드 테라퓨틱스 인크. Use of MIR101 or MIR128 in the treatment of seizure disorders
US11225661B2 (en) * 2018-03-08 2022-01-18 Uriah Bekenstein Methods for controlling seizures by manipulating the levels of microRNA-211 (miR-211) in the brain
CN113924127A (en) * 2019-03-11 2022-01-11 奥克斯纳健康系统公司 micro-RNA regulatory network as biomarker for epileptic seizures in patients with spontaneous intracerebral hemorrhage
CN111218530B (en) * 2020-03-19 2023-10-31 广西壮族自治区水产科学研究院 Primer group and kit for detecting octopoda iridovirus 1 by fluorescence quantitative PCR
EP4155402A1 (en) * 2021-09-22 2023-03-29 Royal College of Surgeons in Ireland Modulation of microrna-335 for the treatment of sodium channelopathies
WO2024008950A1 (en) * 2022-07-08 2024-01-11 Ospedale San Raffaele S.R.L. Transgene cassettes
CN116763809B (en) * 2023-05-31 2024-01-26 广东医科大学附属医院 Application of miR-376b-3p inhibitor in preparation of epilepsy treatment drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2611918A1 (en) * 2010-05-28 2013-07-10 Vereniging Voor Christelijk Hoger Onderwijs, Weten Mirnas involved in the blood brain barrier function

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114410765A (en) * 2022-01-17 2022-04-29 上海大学 Application of miRNA molecular marker in schizophrenia detection
RU2815113C1 (en) * 2023-12-19 2024-03-11 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого" Министерства Здравоохранения Российской Федерации Oligonucleotides for diagnosing epilepsy by quantitative pcr

Also Published As

Publication number Publication date
WO2014096418A3 (en) 2014-08-14
WO2014096418A2 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
IL277912B (en) Targeted therapeutics
GB201223244D0 (en) Micrornas as therapeutics and biomarkers for epilepsy
HK1209762A1 (en) Targeted therapeutics
HK1202051A1 (en) Erythrocyte-binding therapeutics
EP2890672A4 (en) New process
EP2739754A4 (en) Microrna biomarkers
GB201213567D0 (en) Biomarkers
GB201211982D0 (en) Biomarker
GB2513756B (en) Anaerobic process
PL2564983T3 (en) Sharpener
EP2828282A4 (en) Biomarkers
EP2852660A4 (en) Process
GB201210565D0 (en) Biomarkers
PL2914574T3 (en) New process
EP2822601A4 (en) Micrornas and uses thereof
GB2500883B (en) Improved saw-horse
GB201209802D0 (en) Biomarker
GB201202944D0 (en) Biomarker
GB201204391D0 (en) Biomarker
GB201200507D0 (en) Biomarker
AU2012255V (en) Everillo Carex oshimensis
GB201200469D0 (en) Anaerobic process III
GB201216562D0 (en) Biomarker
GB201214806D0 (en) Biomarker
AP2012000556S (en) Kente-zimbabwe flag design

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: UCB PHARMA GMBH

Free format text: FORMER OWNERS: UCB PHARMA GMBH;RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN

AT Applications terminated before publication under section 16(1)